http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108785321-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2017-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108785321-B |
| titleOfInvention | Application of periploca forrestii C21 steroid compound in preparation of IDO inhibitor |
| abstract | The invention belongs to the field of medicines or health-care products, and particularly relates to an application of a periploca forrestii C21 steroid compound in preparation of an IDO inhibitor. According to the invention, researches show that the inhibitory activity of periplocoside L and periplocoside H on intracellular IDO is superior to that of a positive control drug 1-methyltryptophan (1-MT), the periplocoside L and the periplocoside H have obvious inhibitory activity on intracellular IDO, and can be used for treating cancers, Alzheimer's disease, autoimmune diseases, ankylosing spondylitis, bacterial infection, cataract, mood disorders, depression or anxiety disorders. |
| priorityDate | 2017-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.